PET/CT in Esophageal Carcinoma: Applications and Limitations

Squamous cell carcinoma (SqCC) and adenocarcinoma represent approximately 98 % of esophageal malignant tumors. During the last 30 years, the incidence of adenocarcinoma has increased in Western countries (including the USA) where adenocarcinoma currently represents more than 60% of esophageal malignancies, although, worldwide, SqCC continues to be the predominant histologic type. Integrated positron emission tomography (PET)/CT with 2-[fluorine18] fluro-2-deoxy-D-glucose (FDG) is used in many institutions routinely as a tool in the initial staging and then repeated after therapy for the assessment of response to neoadjuvant therapy and detection of recurrent disease in patients with esophageal carcinoma.

from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2vLjMH0